烟酰胺通过促进Foxp3乙酰化增强免疫性血小板减少症中调节性T细胞分化
研究发现免疫性血小板减少症(ITP)患者血浆和CD4+ T细胞中NAD+水平降低,补充NAD+前体烟酰胺(NAM)而非烟酰胺单核苷酸(NMN)可增加ITP小鼠模型中的Treg频率并改善血小板减少。机制上,NAM作为Sirt1抑制剂促进Foxp3乙酰化及稳定性,提示NAM有望成为恢复ITP免疫平衡的新治疗策略。
要点
- ITP患者血浆和CD4+ T细胞中NAD+水平降低
- NAM而非NMN在ITP小鼠模型中增加Treg频率并改善血小板减少
- NAM通过抑制Sirt1促进Foxp3乙酰化和稳定性
核心结论
- NAM通过促进Foxp3乙酰化增强Treg分化,有望成为恢复ITP免疫平衡的新型治疗策略。
研究设计与样本
- 研究检测了ITP患者血浆和CD4+ T细胞中NAD+水平,并在ITP小鼠模型中比较NAM与NMN对Treg频率和血小板减少的影响。
主要发现
- ITP患者血浆和CD4+ T细胞中NAD+水平降低。
- 在ITP小鼠模型中,补充NAM而非NMN可增加Treg频率并改善血小板减少。
- NAM和NMN均能恢复ITP患者CD4+ T细胞的胞质NAD+水平,但仅NAM促进Treg分化。
- ITP患者CD4+ T细胞中Sirt1高表达,可能 contribuir 于NAD+低水平。
- NAM作为Sirt1抑制剂,促进ITP患者初始CD4+ T细胞来源的诱导性Treg中Foxp3乙酰化和稳定性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imbalanced nicotinamide adenine dinucleotide (NAD+) homeostasis has been reported in multiple autoimmune diseases and supplementation with NAD+ precursors has consistently demonstrated positive therapeutic benefits for these conditions. Immune thrombocytopenia (ITP) is an acquired autoimmune disease, in which the decreased number and impaired function of regulatory T cells (Tregs) contribute to the main pathogenesis. Here we found NAD+ level was decreased in the plasma and CD4+ T cells of ITP patients. Supplementation with NAD+ precursor nicotinamide (NAM), but not nicotinamide mononucleotide (NMN), increased Treg frequency and ameliorated thrombocytopenia in an ITP murine model. Moreover, whilst both NAM and NMN restored cytosolic NAD+ level in the CD4+ T cells from ITP patients, only NAM promoted Treg differentiation. Mechanistically, Sirtuin1 (Sirt1), a major consumer of NAD+, was highly expressed in the CD4+ T cells of ITP patients, potentially contributing to the low level of NAD+. NAM, which could act as Sirt1 inhibitor, promoted Foxp3 acetylation and stability in induced Tregs derived from naïve CD4+ T cells of ITP patients. These findings suggest that NAM holds promise as a novel therapeutic strategy for restoring immune balance in ITP.
引用
- Li J, Zhang C, Hu Y, et al. Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia. Br J Haematol. 2024. PMID: 39406393. doi:10.1111/bjh.19820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。